We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
- Authors
Inoue, Akira; Kobayashi, Kunihiko; Usui, Kazuhiro; Maemondo, Makoto; Okinaga, Shoji; Mikami, Iwao; Ando, Masahiro; Yamazaki, Koichi; Saijo, Yasuo; Gemma, Akihiko; Miyazawa, Hitoshi; Tanaka, Tomoaki; Ikebuchi, Kenji; Nukiwa, Toshihiro; Morita, Satoshi; Hagiwara, Koichi; North East Japan Gefitinib Study Group
- Abstract
This multicenter phase II study was undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations without indication for chemotherapy as a result of poor performance status (PS).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 9, p1394
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.18.7658